Contents
The Narrative Problem
There is a growing narrative that growth in the 340B program reflects misuse, abuse, or drift from its original intent.
That narrative is gaining traction in policy discussions, public commentary, and even congressional hearings.
But it is being built on an incomplete view of the data.
If we are going to debate the 340B program, the discussion should be grounded in facts, not selectively framed numbers.
Important Context
These measures capture price, total dollars, and acuity, not utilization alone.
340B spending is measured in dollars.
Drug prices increased substantially.
Spending followed.
Between 2018 and 2024, drug acquisition costs increased by more than 140%.
Patient complexity peaked in 2021 and then stabilized at a baseline significantly higher than pre-pandemic levels.
Any evaluation of 340B growth that does not account for drug pricing is incomplete.
What the Data Does, and Does Not, Prove
These data do not suggest that drug pricing is the only driver of 340B growth.
Other factors contribute, including:
- Changes in care delivery
- Site-of-care shifts
- Consolidation of physician practices
- Program participation trends
But the data does establish something essential.
Central Finding
Drug pricing is a primary driver of growth when measured in dollars.
Ignoring that variable does not clarify the issue; it distorts it.
A Broader Look at Healthcare Economics
Context matters beyond 340B itself.
Pharmaceutical manufacturers
- Frequently operate with profit margins in the 15 to 30 percent range
- Supported by public financial reporting and peer-reviewed analyses.
Hospitals and safety-net providers
- Commonly operate on 1 to 2 percent margins.
- Many have experienced negative operating margins in recent years.
These are not competing claims. They are parallel realities.
What Hospital Margin Data Reinforces
Recent operating margin rankings show that many of the highest-margin health systems in the U.S. are for-profit organizations.
These systems generally do not participate in the 340B program.
At the same time, nonprofit and safety-net systems, the ones most likely to participate in 340B, continue to operate under significant financial pressure.
The Realities Shaping Care Delivery
Rural referral patterns: Patients requiring higher-acuity care are routinely transferred from rural hospitals to larger urban systems due to limited services.
These cases can be as time-sensitive as stroke or trauma, but they can also include conditions as common as appendicitis, where surgical capability or specialist availability may not exist locally.
This is not a function of financial strategy; it is a function of clinical capability and patient need.
In many cases, CMS itself recognizes these referral dynamics through classifications such as Rural Referral Centers (RRCs), which are designed to account for hospitals that serve as regional referral hubs for rural communities despite being in more urbanized areas.
These classifications reflect the realities of healthcare delivery and patient access patterns, not an attempt to circumvent program intent.
Practice consolidation
Independent physician practices are increasingly unable to remain financially viable on their own.
Many face a choice between closing or aligning with larger health systems.
These decisions are often a response to sustained financial pressure rather than being driven solely by expansion strategy.
Health systems are often able to absorb and support these services, in part, because programs like 340B help offset structural reimbursement gaps and maintain access to care within communities.
In practical terms, this can mean:
- Retaining specialty providers locally
- Maintaining infusion capacity within a region
- Reducing delays for time-sensitive treatments
- Limiting the need for patients to travel long distances while managing serious illness and treatment-related side effects
Without that support, access challenges in many communities would likely become significantly more pronounced.
Program Intent Matters
The 340B program was established in 1992 with a clear objective:
“To stretch scarce Federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.”
– (H.R. Rep. No. 102-384(II), at 12 (1992).)
That language is important because it frames the program around stretching limited resources and maintaining patient access, not around static spending levels in isolation.
The healthcare environment today is fundamentally different from what it was in 1992.
- Drug prices have increased significantly
- Patient complexity has evolved
- Financial pressures on providers have intensified.
In that context, growth in the program reflects not only changes in utilization or structure, but also the increasing resources required to achieve the program’s original purpose.
Bottom Line
It takes more today to stretch the same resources as far as possible.
The Rhetoric Problem
There is nothing unreasonable about debating the scope, structure, or future of the 340B program.
But there is a growing disconnect between how the program is described and what the data supports.
Significant resources are being directed toward shaping a narrative that positions safety-net providers as the primary driver of rising drug spending.
That framing is gaining traction, and it deserves scrutiny. When a narrative gains momentum without context, it can influence policy decisions that directly affect access to care.
Compass Perspective
340B has grown.
That is not in dispute.
What is in dispute is why.
The data does not support a simple explanation.
Growth in dollar terms is, to a significant extent, a function of drug pricing.
That does not resolve every question about the program, but it is a critical part of the answer. The question is not whether 340B has grown, but whether we are willing to accurately acknowledge what is driving that growth.
How we interpret these trends matters. Policy decisions made without a full understanding of these dynamics can directly impact access to care in communities across the country.
Final Thought
If the goal is to strengthen healthcare delivery, the starting point must be an honest understanding of what the data actually shows.
Methodology and Sources
All values indexed to 2018 = 100 for comparability across measures with different scales.
Data Sources:
- CMS National Average Drug Acquisition Cost (NADAC) Files
- CMS Medicare Case Mix Index (CMI) Data
- HRSA 340B Program Data & Reports
- Becker’s Hospital Review Operating Margin Rankings
- Kaufman Hall National Hospital Flash Reports
- Damodaran – Margins by Sector (Pharmaceuticals)
- Ledley et al. – JAMA (2020)
